material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.
As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our prospectus dated November 19, 2020 filed with the SEC on November 23, 2020. However, we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Unregistered Sales of Equity Securities
Simultaneously with the closing of our IPO, pursuant to the Private Placement Warrants Purchase Agreement, the Company completed the private sale of an aggregate of 6,481,550 Private Placement Warrants to Kingswood Global Sponsor LLC (“Sponsor”), generating gross proceeds to the Company of $6,481,550. The Private Placement Warrants are identical to the Public Warrants sold in the IPO except that the Private Warrants, so long as they are held by our Sponsor or its permitted transferees, (i) will not be redeemable by the Company, (ii) may not (including the shares of Class A common stock issuable upon exercise of these warrants), subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after the completion of the Company’s initial business combination, (iii) may be exercised by the holders on a cashless basis and (iv) will be entitled to registration rights. The issuance of the Private Placement Warrants was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.
Use of Proceeds
On November 24, 2020, we completed the sale of 10,000,000 Units at $10.00 per Unit, generating gross proceeds of $100,000,000.
Simultaneous with the closing of the Public Offering, we completed the sale of 6,050,000 Private Warrants, at a price of $1.00 per Private Warrant, generating gross proceeds of $6,050,000, and completed the issuance to Oppenheimer & Co. Inc. 104,000 Underwriter Units in lieu of 0.9% of the gross proceeds of the Public Offering.
In connection with the Public Offering, the underwriters were granted a 30-day option from the date of the prospectus for the Public Offering to purchase up to 1,500,000 additional units to cover over-allotments, if any. Simultaneously with the closing of the Public Offering, the underwriters elected to exercise their full 1,500,000 Public Units over-allotment option which, at $10.00 per Unit, generated gross proceeds of $15,000,000. The Company, in parallel, consummated the private placement of an additional 431,550 Private Warrants at a price of $1.00 per Private Warrant, which generated total additional gross proceeds of $431,550.
Following our Initial Public Offering and the sale of the Private Warrants, a total of $117,848,550 ($10.25 per Unit) was placed in the Trust Account. We incurred $7,104,274 in Initial Public Offering related costs, including $2,300,000 of underwriting fees ($1,260,000 in cash and $1,040,000 in the form of 104,000 Units at $10.00), $4,025,000 of deferred underwriting discount and $779,274 of other costs.
As of September 30, 2021, we had marketable securities held in the Trust Account of $117,858,560 (including approximately $81 of interest income) consisting of mutual funds. Interest income on the balance in the Trust Account may be used by us to pay taxes. Through September 30, 2021, we did not withdraw any interest earned on the Trust Account to pay our taxes.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.